Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Italy
In short"fine Foods & Pharmaceuticals N.t.m. S.p.a." is profitable, burns cash and carries moderate debt, with revenue growing (+3.4% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 6.5% | 38/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 4.0% | 36/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 7.6% | 38/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 5.6% | 37/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.75× | 79/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.64× | 76/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.35× | 76/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 5.39× | 37/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.54 | 37/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -1.1% | 15/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | -0.28× | 0/100 |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 4 | 58/100 |
| Revenue growth volatility | 10.4% | 73/100 |
| Operating margin volatility | 3.2% | 80/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 6.8% | 54/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 195 | 208 | 253 | 245 | 253 |
| Operating income | 5 | (1) | 1.1 | 15 | 16 |
| Interest expense | 0.8 | 2.2 | 5 | 3.5 | 3 |
| Pre-tax income | (4.6) | (14) | (1.9) | 12 | 14 |
| Income tax | (3.2) | (4.7) | 1.7 | 3.7 | 3.5 |
| Net income | (1.4) | (9.5) | (3.5) | 8.2 | 10 |
| Diluted EPS | −€0.06 | −€0.37 | −€0.14 | €0.33 | €0.41 |
2.54 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Mar 24, 2026